IRREVERSIBLE BLOCKADE OF THE THROMBOXANE A2/PROSTAGLANDIN H2 RECEPTOR OF HUMAN PLATELETS BY AZIDO-BSP

1987 ◽  
Author(s):  
H Zehender ◽  
E C Witte ◽  
K Stegemeier ◽  
A Patscheke
Keyword(s):  
Shape Change ◽  
Thromboxane A2 ◽  
High Specificity ◽  
Short Wave ◽  
Human Platelets ◽  
Serotonin Release ◽  
Irreversible Inhibition ◽  
High Concentrations ◽  
Very High ◽  
Platelet Shape

Azido-BSP (4-[2-(4-azido-benzenesulphonylamino)-ethyl]phen-oxyacetic acid) is a photolabile derivative of the competitive thromboxane A2 /prostaglandin H2 (TXA2/PGH2) receptor antagonist sulotroban (=BM 13.177). If protected from short wave light, azido-BSP reversibly inhibited the platelet shape change induced by the PGH2 analogue U 46619 but notthe shape change induced by ADP or PAF. Schild analysis revealed an apparent KD=0.2 μM with washed platelets. The irreversible inhibition requiredirradiation of the platelet suspensionwith UVlight (254 nm) for 5 minutes in the presenceof azido-BSP. After this treatment,the platelets were washed twice and used forplatelet function tests. Treatment with 0.5 μM of azido-BSP suppressed the U 46619(10 μM)-induced (3H)serotonin release and 1 μM of azido-BSP was necessary to block the U 46619(2 μM)-inducedaggregation.The platelet shape change induced by U 46619 (0.01μM) was only partially inhibited, even at very high concentrations (50μM) of the antagonist.This suggests that a small portion of the TXA2/PGH2 receptors could not be blocked bythe photoaffinity treatment with azido-BSP. After treatment with 1 μM azido-BSP, the shape change stimulated by ADP or PAF was not reduced. This indicates a high specificity of thephotoaffinity ligand for the TXA2/PGH2 receptor. It is concluded that UV irradiation of azido-BSP generates anitrene intermediate that covalently links to the majority of the TXA2/PGH2 receptors. Azido-BSP provides a specific tool for tagging and subsequent purification of the TXA2/PGH2 receptor of platelets.(Supported by the Deutsche Forschungsgemeinschaft, Grant Pa263).

scholarly journals Effects of Lectins on Blood Platelets from Various Species

1977 ◽  
Author(s):  
O. Tangen ◽  
B. Karlstam ◽  
S. Bygdeman
Keyword(s):  
Shape Change ◽  
Blood Platelets ◽  
Human Platelets ◽  
Serotonin Release ◽  
Variable Degree ◽  
Con A ◽  
Platelet Release ◽  
Induced Aggregation ◽  
Aggregation Of Platelets ◽  
Platelet Shape

Earlier it has been shown that different lectins induce a variable degree of aggregation of platelets. The present study confirmed previous data and demonstrated that wheat germ agglutinin (WGA) was very active, 1eucoagglutinin had about a tenth of the activity of WGA on a concentration basis, and Con A had a weak aggregating effect on human gel filtered platelets (GFP). Soy bean lectin did not aggregate human GFP.The fact that adenosine inhibited WGA- and leucoagglutinin-induced aggregation that WGA and Con A caused serotonin release, and that the aggregation- curves indicated platelet shape change are indications that the lectins influenced glycosyl moieties involving one or more molecules relevant to release and aggregation reaction.GFP were markedly more responsive to the lectins than platelets in plasma, probably due to interfering glycosyl groups amongst the plasma constituents.Platelets from man, rabbit, rat, cow and pig reacted differently towards the lectins, human platelets being the most reactive and bovine and porcine platelets being almost unreactive. These results pose intriguing questions regarding the glycosyl content of platelet membranes in different species and their relation to platelet release and aggregation.

Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets

1985 ◽  
Vol 249 (1) ◽  
pp. H8-H13
Author(s):  
L. D. Brace ◽  
D. L. Venton ◽  
G. C. Le Breton
Keyword(s):  
Receptor Antagonist ◽  
Calcium Release ◽  
Shape Change ◽  
Thromboxane A2 ◽  
Cytosolic Calcium ◽  
Human Platelets ◽  
Calcium Mobilization ◽  
Receptor Interaction ◽  
Calcium Sequestration ◽  
Platelet Shape

We previously demonstrated that thromboxane A2 and/or prostaglandin H2 (TXA2/PGH2), ADP, and A23187 cause calcium mobilization in intact human platelets. Other studies have also shown that platelet shape change and aggregation induced by a variety of platelet agonists can be reversed by specific antagonists. In the present study, we used the fluorescent calcium probe chlortetracycline to evaluate whether the reversal of platelet activation involves a resequestration of intraplatelet calcium. It was found that the TXA2/PGH2 receptor antagonist 13-azaprostanoic acid (13-APA) reversed calcium mobilization and shape change induced by AA but not that induced by ADP. A similar specificity of action was observed using the specific ADP receptor antagonist, ATP, in that ATP only reversed ADP-induced calcium release and shape change. In contrast, prostacyclin reversed both AA and ADP-induced calcium redistribution and shape change. In the latter experiments, a net calcium sequestration was actually observed on prostacyclin addition. These findings indicate that the resequestration of released calcium leads to platelet deactivation. Furthermore, there appear to be at least two mechanisms by which a reduction in cytosolic calcium can be produced: specific interruption of the agonist-receptor interaction, for example, 13-APA antagonism of TXA2/PGH2; and stimulation of platelet adenosine 3',5'-cyclic monophosphate production by prostacyclin and consequent calcium sequestration.

Genetic and Pharmacological Analyses of Involvement of Src-family, Syk and Btk Tyrosine Kinases in Platelet Shape Change

2001 ◽  
Vol 85 (02) ◽  
pp. 331-340 ◽  
Author(s):  
Markus Bauer ◽  
Petra Maschberger ◽  
Lynn Quek ◽  
Stephen Briddon ◽  
Debabrata Dash ◽  
...  
Keyword(s):  
Tyrosine Kinases ◽  
Shape Change ◽  
Thromboxane A2 ◽  
Human Platelets ◽  
Src Family Kinases ◽  
G Protein Coupled Receptors ◽  
Protein Tyrosine Phosphorylation ◽  
G Protein Coupled ◽  
Platelet Shape ◽  
Stimulation Of

SummaryPlatelet shape change was found to be associated with an increase in protein tyrosine phosphorylation upon stimulation of thrombin-, ADPand thromboxane A2-G-protein coupled receptors in human platelets and thromboxane A2 receptors in mouse platelets. By using PP1 and PD173956, two structurally unrelated specific inhibitors of Src-family tyrosine kinases, and mouse platelets deficient in the Src-kinase Fyn or Lyn, we show that Src-family kinases cause the increase in protein tyrosine phosphorylation. We further detected that the non-Src tyrosine kinase Syk was activated during shape change in a manner dependent on Src-family kinaseactivation. The pharmacological experiments and the studies on Fyn-, Lyn- and Syk-deficient mouse platelets showed that neither Src-family kinases nor Syk are functionally involved in shape change. Also human platelets deficient of the tyrosine kinase Btk showed a normal shape change. Binding of PAC-1 that recognizes activated integrin αIIb β3 complexes on the platelet surface was enhanced during shape change and blocked by inhibition of Src-kinases. We conclude that the activation of Src-kinases and the subsequent Syk stimulation upon activation of G-protein coupled receptors are not involved in the cytoskeletal changes underlying shape change of human and mouse platelets, but that the stimulation of this evolutionary conserved pathway leads to integrin αIIb β3 exposure during shape change.

Physiological Effects of Nonimmune Platelet Associated Immunoglobulin G

1981 ◽  
Vol 45 (01) ◽  
pp. 027-033 ◽  
Author(s):  
K Sugiura ◽  
M Steiner ◽  
M Baldini
Keyword(s):  
Shape Change ◽  
Fluorescein Isothiocyanate ◽  
Recovery Phase ◽  
Human Platelets ◽  
Serotonin Release ◽  
Platelet Volume ◽  
Igg Antibody ◽  
Heterologous Antiserum ◽  
Igg Binding ◽  
Series Of Experiments

SummaryThe function of nonimmune IgG associated with platelets is unknown. In a series of experiments we have investigated this problem, relating amount of platelet-associated IgG (PAIgG) to platelet volume, serotonin release, adherence of platelets to monocytes and platelet senescence. Most of these studies were performed with human platelets. Platelets freed of preexisting PAIgG by incubation at 22° C were incubated with IgG in a series of concentrations ranging from 0.4 — 27.0 X10-6 M. The IgG preparations used were demonstrably free of aggregated forms of the protein. The amount of PAIgG bound to platelets was determined by the use of fluorescein isothiocyanate-conjugated anti-IgG antibody (F-anti-IgG antibody) which was quantified in a fluorospectrophotometer. Newly bound IgG was assayed similarly by the use of F-IgG. A dose-dependent increase in platelet volume was associated with the binding of nonimmune IgG by platelets. The process which leveled off at an IgG concentration of 1.2 —1.5 X10-5 M was almost fully reversible and was not due to platelet shape change or aggregation. Release of serotonin from IgG-treated platelets was relatively small but to the extent that it occurred was positively related to the IgG concentration to which platelets were exposed. Adherence to autologous monocytes studied quantitatively by the use of formaldehyde-fixed cells was also positively related to the amount of IgG on the platelets. Normal or IgG-defident serum had a potent inhibitory (noncompetitive) action on the binding of F-IgG and F-anti-human IgG antibody to human platelets. Cohorts of platelets prepared in rabbits during the recovery phase of immunological thrombocytopenia induced by injection of heterologous antiserum, showed an age-dependent increase of PAIgG and of IgG binding. These results suggest that PAIgG plays a role in the clearance of senescent platelets.

scholarly journals Mechanism of Action of Halofenate, A Platelet Inhibitor

1977 ◽  
Author(s):  
G. R. Favis ◽  
R. W. Colman
Keyword(s):  
Platelet Aggregation ◽  
Platelet Rich Plasma ◽  
Shape Change ◽  
Thiobarbituric Acid ◽  
Serotonin Release ◽  
Prostaglandin Synthesis ◽  
Second Phase ◽  
Change Curve ◽  
Cellulose Column ◽  
Platelet Shape

Halofenate (Hal) has previously been shown to inhibit epinephrine (Epi) and ADP induced platelet aggregation and C14-serotonin release. We further investigated the site of action of Hal by examining platelet shape change as a membrane event and malondialdehyde (MDA) formation as a measure of prostaglandin synthesis. Platelet-rich-plasma (PRP) with and without Hal wasdiluted in an EDTA buffer and examined in a spectrophotometer modified for stirring and maintained at 37°. ADP induced increase in absorbance was recorded and the velocity of the shape change curve was plotted against ADP concentration. MDA production was measured by the thiobarbituric acid assay and utilized a DEAE-52 cellulose column to concentrate the chromogen. Hal in pharmacologic concentrations (.96mM) had no effect on Epi induced primary aggregation or on ADP induced shape change. However, at higher than pharmacologic amounts (3.36mM), Hal did inhibit ADP induced shape change. Epi-induced MDA formation (.18μM-.33μM) normally occurs concomitant with the second phase of aggregation and serotonin release but was markedly decreased by Hal (.06μM-.085μM). This inhibition was not due to a direct effect on prostaglandin synthesis since sodium arachi-donate (1mM) caused secondary aggregation in PRP treated with Hal but not PRP treated with aspirin (4mM). Hal (.96mM) does not seem to inhibit platelet aggregation through an inhibition of ADP induced shape change or of Epi induced primary aggregation. Since Hal treated platelets respond to arachidonate, Hal must work at some earlier step than arachidonate induced prostaglandin synthesis. We suggest that this may be an alteration of the platelet membrane structure which makes ADP and Epi binding sites less accessible or which impairs arachidonic acid release by phospholipase. Decreased MDA formation and inhibition of aggregation would then be secondary to this membrane change.

Evidence for Ca2+-independent phosphorylation of human platelet myosin

1987 ◽  
Author(s):  
J L Daniel ◽  
M Rigmaiden
Keyword(s):  
Protein Kinase C ◽  
Protein Kinase ◽  
Myosin Light Chain ◽  
Shape Change ◽  
Human Platelets ◽  
Myosin Phosphorylation ◽  
Kinase C ◽  
Synthetic Inhibitor ◽  
Measurable Change ◽  
Platelet Shape

Phosphorylation of platelet myosin is thought to be required for activation of the contractile events occurring during platelet activation. At present the only known mechanism for Onitiating myosin phosphorylation is through a Ca2+-calmodulin-dependent activation of myosin light chain kinase. However, our previous studies using the fluorescent Ca2+-indicator quin2 indicated that both platelet shape change and myosin phosphorylation could be induced in an EGTA-containing media in the absence of a measurable change in cytosolic free Ca2+ concentration (Hallam, Daniel, Kendrick-Jones & Rink. Biochem. J. 232 (1985) 373). In order to confirm this finding, we fyave investigated the regulation of myosin phosphorylation usin^+a preparation of electrically-permeabilized platelets and Ca2+ buffers to control the internal Ca2+ concentration. Fifty percent myosin phosphorylation was obtained at 700 nM Ca2+. When thrombin (5 U/ml) was added to this system, this curve shifted both to the left and upward; 50% myosin phosphorylation was obtained at 400 nM Ca2+.A synthetic inhibitor of protein kinase C, H7, had no effect on myosin phosphorylation in the absence of agonist but did inhibit the thrombin-induced shift to left suggesting that protein kinase C may modulate myosin phosphorylation. We also compared the effects of H7 agonist-induced myosin phosphorylation and shape change in control and an quin2 loaded platelets. Comparable inhibition of both phosphorylation and the rate of shape change was observed with both quin2 and H7. Addition of H7 to quin2-loaded platelets resulted in complete inhibition of both agonist-induced shape change and myosin phosphorylation. These results indicate that both protein kinase C and Ca2+-dependent reactions are involved in complete expression of myosin phosphorylation in human platelets.

scholarly journals Factor VIII-induced superaggregation of human platelets

Blood ◽  
1982 ◽  
Vol 60 (6) ◽  
pp. 1359-1369 ◽  
Author(s):  
EP Kirby ◽  
DC Mills ◽  
H Holmsen ◽  
M Russo
Keyword(s):  
Factor Viii ◽  
Cytochalasin B ◽  
Dextran Sulfate ◽  
Adenosine Diphosphate ◽  
Human Platelets ◽  
Ionophore A23187 ◽  
High Concentrations ◽  
Induced Aggregation ◽  
Very High ◽  
Bovine Factor

Abstract High concentrations of bovine factor VIII cause clumping of platelets into a few very large aggregates. This response is termed superaggregation. It is distinct from factor-VIII-induced agglutination but is also independent of both extracellular calcium ions and platelet energy metabolism. Neither agglutinating lectins nor aggregating agents, including thrombin, ADP, the ionophore A23187, and U46619, a prostaglandin analog, can induce superaggregation, even at very high concentrations. Washed platelets undergo superaggregation, and superaggregation does not increase the amounts of fibrinogen or albumin trapped by agglutinated platelets. It is not inhibited by membrane- stabilizing drugs or by colchicine or cytochalasin-B. Formaldehyde and glutaraldehyde prevent superaggregation without affecting the binding of radiolabeled factor VIII to the platelets. Superaggregated platelets are separated by approximately 50 nm and are not shape-changed or degranulated. In adenosine diphosphate (ADP) induced aggregation, the platelets are distorted and only 30 nm apart. Superaggregation is reversed by dextran sulfate, and the dispersed platelets are still able to respond to ADP. Our observations are consistent with the binding of high molecular weight multimers of bovine factor VIII to more than one receptor on each platelet, with superaggregation occurring through recruitment of additional receptors. This process may be interrupted by protein crosslinking reagents, such as formaldehyde and glutaraldehyde.

scholarly journals Regulation of LIM-kinase 1 and cofilin in thrombin-stimulated platelets

Blood ◽  
2006 ◽  
Vol 107 (2) ◽  
pp. 575-583 ◽  
Author(s):  
Dharmendra Pandey ◽  
Pankaj Goyal ◽  
James R. Bamburg ◽  
Wolfgang Siess
Keyword(s):  
Shape Change ◽  
Rho Kinase ◽  
Lim Kinase ◽  
Kinase Activation ◽  
Integrin Αiibβ3 ◽  
Lim Kinase 1 ◽  
Filament Dynamics ◽  
Cofilin Phosphorylation ◽  
High Concentrations ◽  
Platelet Shape

Abstract Cofilin is a regulator of actin filament dynamics. We studied whether during platelet activation Rho kinase stimulates LIM kinase (LIMK) leading to subsequent phosphorylation and inactivation of cofilin. Platelet shape change and aggregation/secretion were induced by low and high concentrations of thrombin, respectively. We found that during these platelet responses Rho kinase activation was responsible for mediating rapid Thr508 phosphorylation and activation of LIMK-1 and for the F-actin increase during shape change and, in part, during secretion. Surprisingly, during shape change cofilin phosphorylation was unaltered, and during aggregation/secretion cofilin was first rapidly dephosphorylated by an okadaic acid–insensitive phosphatase and then slowly rephosphorylated by LIMK-1. LIMK-1 phosphorylation and cofilin dephosphorylation and rephosphorylation during aggregation were independent of integrin αIIbβ3 engagement. Cofilin phosphorylation did not regulate cofilin association with F-actin and was unrelated to the F-actin increase in thrombin-activated platelets. Our study identifies LIMK-1 as being activated by Rho kinase in thrombin-stimulated platelets. Two counteracting pathways, a cofilin phosphatase and LIMK-1, are activated during platelet aggregation/secretion regulating cofilin phosphorylation sequentially and independently of integrin αIIbβ3 engagement. Rho kinase–mediated F-actin increase during platelet shape change and secretion involves a mechanism other than LIMK-1–mediated cofilin phosphorylation, raising the possibility of another LIMK substrate regulating platelet actin assembly.

Sign in / Sign up

Export Citation Format

Share Document